SMARCA4 and cancer: Moreover, KRAS/SMARCA4 co-mutated patients across multiple NSCLC studies were found to have inferior survival outcomes throughout various types of cancer treatment analysis, including chemotherapy, ICI, and targeted therapy [21,22,23,24,25].